PRGO Perrigo Company plc

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Perrigo makes private-label over-the-counter drugs, which sounds like a reliable business, but there are warning signs to consider before you buy it.

Market share gains offset sales decline as Perrigo completes Dermacosmetics divestiture.

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Perrigo stock has fallen sharply over the past few years, yet the current valuation checks suggest the market may now be pricing it on the cheap side. After a period of weak long term returns, investors are weighing whether the recent bounce in the share price is the start of a re rating or just a short term reaction. The share price has declined 61.9% over the past 3 years, which sets expectations low and can create room for a valuation reset if fundamentals hold up. Future revenue growth...

Perrigo (NYSE:PRGO) reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving

Why Perrigo Stock Is Back in Focus After Q2 Earnings Perrigo (PRGO) is drawing fresh attention after second quarter 2026 adjusted earnings per share came in ahead of consensus, supported by strong Infant Formula sales and a reaffirmed full year outlook for declining net sales. For investors, this mix of outperformance on adjusted earnings, weaker overall sales and a maintained guidance range for net sales decline between 5.5% and 1.5% raises practical questions about how the stock’s recent...

PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.

Moby summary of Perrigo Company plc's Q2 2026 earnings call

Perrigo Co PLC (PRGO) navigates a challenging quarter with strategic wins in infant formula and innovation, despite a 3.1% core net sales dip.